Home>Startup Bluedrop Medical chosen for the URGO Mentorship Program

05 March 2018

Startup Bluedrop Medical chosen for the URGO Mentorship Program

URGO Group is delighted to announce the winner of its URGO Mentorship Program, Bluedrop Medical, an Irish start-up which is developing a device that can predict the formation of a diabetic foot ulcer, a major complication of diabetes.

 For one year, URGO Group will support Bluedrop Medical on matters such as marketing, intellectual property, clinical trials, scale up and market launch.

Last June, URGO Group launched this tailor-made mentoring program to help start-ups in medical technology to increase their chances of success to develop and market their innovations. Nearly 50 French and European start-ups responded to the call for applications in 2017.


In October, six pre-selected start-ups presented their project to a panel of experts at a “Demo Day”, in Paris, France. At the end of this day, three innovative start-ups were chosen for a final three-month “Give and Take” phase, during which finalists were able to enjoy initial support from URGO Group.URGO Group was able to further explore how it could support development of the future winner’s project by analysing its technology and business model.




Reducing the burden of diabetic foot ulcers could improve lives and save healthcare systems great costs

The innovation developed by Bluedrop Medical could prevent hundreds of thousands of amputations each year thanks to a simple daily scan of the patient’s foot, performed with a home-based device and analysed by an advanced algorithm capable of detecting abnormalities.


About Diabetic Foot Ulcers

  •  19 to 34% of diabetic patients will suffer from a diabetic foot ulcer at least once in their lifetime¹
  • With one amputation every 20 seconds, diabetes is the world’s leading cause of amputation ²
  • Within the diabetic population in France, 9000 people are affected each year³
  • Up to 70% of patients could die within 5 years after an amputation¹


These alarming figures convey a real public health issue, both for patients, for whom this could be life threatening, and for health systems which have to bear the costs.

Until now, no local treatment, available for all health professionals, in hospitals and in private practices had proven to be effective in treating these wounds.

In 2018, URGO Group’s medical division, Urgo Medical, made a major step in treating diabetic foot ulcer, with the announcement of the results of its comparative clinical trial, EXPLORER, the first trial that demonstrates the efficacy of a dressing in the healing of this pathology.

This trial was published in the LANCET Diabetes & Endocrinology, one of the most well-known medical and scientific reviews in the world.




  1. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017; 376: 2367-75
  2. Whiting, D. R., Guariguata, L., Weil, C., and Shaw, J. 2011. “IDF Diabetes Atlas: Global Estimates of the Prevalence of Diabetes for 2011 and 2030.” Diabetes Res. Clin. Pract. 94 (3): 311-21.
  3. Rapport au ministre chargé de la Sécurité sociale et au Parlement sur l’évolution des charges et des produits de l’Assurance Maladie au titre de 2017 (loi du 13 août 2004). 7 juillet 2016. P.75).

Share this article

sur twitter sur linkedin on facebook by mail

print this article :